Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 199
Filter
Add more filters










Publication year range
1.
J Pharmacol Exp Ther ; 301(2): 527-35, 2002 May.
Article in English | MEDLINE | ID: mdl-11961053

ABSTRACT

As part of a project to develop treatment agents for cocaine abuse, (+/-)-threo-methylphenidate (TMP) and 11 analogs were characterized biochemically and behaviorally to assess their potential as anti-cocaine medications. The compounds contained aryl and/or nitrogen substitutions, and/or replacement of the ester function by an alcohol or ether. All of the analogs, except for the N-methyl-substituted compounds, showed increased inhibitory potency against (3)H-(-)-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane 1,5-naphthalenedisulfonate ([(3)H]WIN 35,428) ([(3)H]WIN) binding to the dopamine transporter, compared with TMP. In general, parallel results were obtained for inhibition of [(3)H]dopamine ([(3)H]DA) uptake. Although compounds with N-substitutions were proportionally less potent at blocking DA uptake than WIN binding (compared with the unsubstituted compounds), one such compound that was 6-fold more potent against [(3)H]WIN binding than [(3)H]DA uptake did not attenuate inhibition by cocaine of synaptosomal [(3)H]DA transport. The compounds were significantly less potent in displacing [(3)H]citalopram binding from the serotonin transporter. In cocaine discrimination studies in rats, all but two of the analogs (both N-substituted) completely generalized with the cocaine stimulus. Robust positive correlations were observed between potency in the drug discrimination assay and activity at the dopamine transporter, but not the serotonin transporter. When tested for their ability to alter cocaine discrimination, four of the analogs (three of which had N-substitutions and shallow dose-response curves as cocaine substitutes) actually enhanced cocaine discrimination, often at combined doses of cocaine and test compound that were inactive when given separately. Taken together, the results suggest that TMP analogs may have potential as substitution therapies for the treatment of cocaine abuse.


Subject(s)
Discrimination Learning/drug effects , Thymidine Monophosphate/pharmacology , Animals , Dose-Response Relationship, Drug , Male , Models, Animal , Rats , Rats, Sprague-Dawley , Thymidine Monophosphate/analogs & derivatives
2.
Psychopharmacology (Berl) ; 157(3): 305-12, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11605087

ABSTRACT

RATIONALE: Daily, 3-h separations from the dam on postnatal days 2-14 produce long-lasting changes in behavioral and neuroendocrine responses to stressors and sensitivity to acute morphine in Long-Evans rats. OBJECTIVE: We tested whether offspring that were separated from their dam for 3 h daily (MS) on postnatal days 2-14 exhibit altered sensitivity to chronic morphine, compared to animals that experienced only brief (15 min) separations (H) from the dam or that were left undisturbed (NH) during the same period. METHODS: Subjects received 1 week SC infusion of either morphine, or saline via osmotic pumps. Twenty-hours after pump removal, the global opioid withdrawal scores were recorded. Four hours later, animals were tested for antinociception (tail-flick and hot-plate tests) during cumulative morphine administration. RESULTS: MS males and MS females undergoing withdrawal from chronic morphine had higher global withdrawal scores compared to NH controls. MS males (but not MS females) were less sensitive to the antinociceptive effects of morphine compared to H and NH controls, primarily in the hot-plate test, regardless of whether they had received a saline or a morphine infusion. MS males consistently exhibited significant morphine tolerance, whereas control males failed to exhibit tolerance either in the hot-plate test (NH group) or in both antinociception assays (H group). In contrast, tolerance was exhibited by all females in both tests for antinociception. CONCLUSIONS: These data indicate that repeated neonatal maternal separation alters sensitivity to chronic morphine administration in a sex-dependent manner.


Subject(s)
Analgesics, Opioid/pharmacology , Animals, Newborn/psychology , Morphine Dependence/psychology , Morphine/pharmacology , Animals , Drug Tolerance , Female , Male , Maternal Deprivation , Pain Measurement/drug effects , Rats , Rats, Long-Evans , Reaction Time/drug effects , Sex Characteristics , Substance Withdrawal Syndrome/psychology
3.
Behav Pharmacol ; 12(2): 101-8, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11396514

ABSTRACT

Repeated administration of morphine to rats increases their sensitivity to behavioral effects of morphine as well as to those of psychomotor stimulants, such as cocaine and amphetamine. Conversely, stimulant-induced sensitization to behavioral effects of stimulants often results also in sensitization to behavioral effects of morphine. However, in nigrally lesioned rats, repeated injections of morphine produce sensitization to morphine-induced turning but not to turning induced by cocaine or amphetamine. The present study was performed to determine whether giving repeated cocaine injections to nigrally lesioned rats would produce cross-sensitization to morphine-induced turning. Daily injections of 10 mg/kg cocaine (i.p.) enhanced the turning response to cocaine by day 8, but not the turning response to 3.0 mg/kg morphine (s.c.). The response to morphine increased equally in both cocaine- and saline-treated animals after they had received morphine once. Dose-response curves for morphine (1.0-10 mg/kg) and for cocaine (3.0-30 mg/kg), determined during weeks 3 and 4, were the same in rats receiving daily injections of cocaine or daily injections of saline. Thus, although repeated exposure to cocaine or morphine resulted in sensitization to turning induced by each drug, respectively, there was no cross-sensitization between the two drugs. In contrast to other behaviors, rotational behavior does not seem to exhibit cross-sensitization between morphine and psychomotor stimulants.


Subject(s)
Cocaine-Related Disorders/physiopathology , Cocaine/pharmacology , Morphine/pharmacology , Stereotyped Behavior/physiology , Substantia Nigra/physiopathology , Animals , Brain Mapping , Dose-Response Relationship, Drug , Drug Interactions , Male , Rats , Rats, Sprague-Dawley , Stereotyped Behavior/drug effects , Substantia Nigra/drug effects
4.
Psychopharmacology (Berl) ; 155(2): 180-6, 2001 May.
Article in English | MEDLINE | ID: mdl-11401007

ABSTRACT

RATIONALE: Inhibitors of neuronal dopamine uptake, such as GBR 12909, decrease IV cocaine self-administration by laboratory animals and have been proposed as potential therapeutic agents for abuse of psychomotor stimulant drugs. OBJECTIVES: This study was performed to determine how GBR 12909 alters the discriminative stimulus effects of methamphetamine and cocaine. METHODS: Rats were trained to discriminate between IP injections of 10 mg/kg cocaine and saline and were tested for stimulus generalization to cocaine, GBR 12909, and methamphetamine. Based upon the ED50 of the individual drugs, combinations of GBR 12909 and either cocaine or methamphetamine were tested that comprised a) 1 part GBR 12909 and 2 parts cocaine or methamphetamine, or b) 2 parts GBR 12909 and 1 part cocaine or methamphetamine. RESULTS: GBR 12909 and cocaine were equipotent and 30-fold less potent than methamphetamine in producing cocaine-like discriminative effects. GBR 12909 and cocaine produced cocaine-like discriminative effects synergistically in the ratio of 1 part GBR 12909:2 parts cocaine (0.16+0.32 to 1.92+ 3.87 mg/kg) and nearly synergistically in the ratio of 2 parts GBR 12909:1 part cocaine (0.32+0.16 to 3.92+ 1.91 mg/kg). GBR 12909 and methamphetamine (0.32+0.02 to 3.20+0.22 mg/kg or 0.65+0.01 to 6.53+0.1 mg/kg) were simply additive in both sets of fixed-ratio dose combinations. CONCLUSIONS: The synergy of GBR 12909 and cocaine and the additivity of GBR 12909 and methamphetamine run counter to the presumed mechanisms of action of these drugs at dopamine nerve terminals, which might have implications for the use of GBR 12909 in the treatment of addiction to cocaine or amphetamines.


Subject(s)
Cocaine/pharmacology , Discrimination, Psychological/drug effects , Dopamine Uptake Inhibitors/pharmacology , Methamphetamine/pharmacology , Piperazines/pharmacology , Animals , Discrimination Learning/drug effects , Dopamine/metabolism , Dose-Response Relationship, Drug , Drug Synergism , Generalization, Stimulus/drug effects , Male , Motor Activity/drug effects , Neurons/drug effects , Neurons/metabolism , Rats , Rats, Sprague-Dawley
5.
Brain Res Bull ; 54(6): 649-54, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11403991

ABSTRACT

Recent studies indicate that Long-Evans rats separated from their dam for 3 h daily over the first 2 weeks of life (maternally separated [MS] rats) exhibit exaggerated behavioral and neuroendocrine responses to stress as adults compared to handled (H) or non-handled (NH) control animals. Our aim was to determine whether repeated neonatal maternal separation results in altered sensitivity to the opioid agonist morphine in male and female adult rats. Sensitivity to morphine was assessed using hot-plate and tail-flick tests. Morphine was less potent inducing antinociception in MS males compared to same-sex controls in the hot-plate, but not in the tail-flick test. Decrease in sensitivity to morphine in MS females compared to same-sex controls was present only as a trend in the hot-plate, but not in the tail-flick test. These results suggest that neonatal maternal separation results in long-lasting changes in opioid responsiveness primarily in male rats.


Subject(s)
Analgesics, Opioid/pharmacology , Maternal Deprivation , Morphine/pharmacology , Nociceptors/metabolism , Pain/physiopathology , Receptors, Opioid/metabolism , Stress, Physiological/physiopathology , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Central Nervous System/drug effects , Central Nervous System/growth & development , Central Nervous System/metabolism , Female , Male , Neurons/drug effects , Neurons/metabolism , Nociceptors/drug effects , Pain/metabolism , Pain Threshold/drug effects , Pain Threshold/physiology , Rats , Rats, Long-Evans , Reaction Time/drug effects , Reaction Time/physiology , Receptors, Opioid/drug effects , Sex Factors , Stress, Physiological/metabolism
6.
Pharmacol Biochem Behav ; 69(1-2): 59-70, 2001.
Article in English | MEDLINE | ID: mdl-11420069

ABSTRACT

Current evidence indicates that the acute locomotor stimulant effects of caffeine involve dopamine (DA) receptor activation; however, few studies have investigated the role of DA receptors in mediating the development of tolerance to caffeine. Therefore, the present study was designed to determine the degree to which DA receptors mediate the development of tolerance to the locomotor stimulant effects of caffeine. Caffeine was examined alone and in combination with haloperidol (HAL), GBR 12909, nisoxetine and fluoxetine. HAL dose-dependently and completely blocked the acute effects of caffeine on locomotor activity, and the highest dose of GBR 12909 enhanced the effects of caffeine. Neither nisoxetine nor fluoxetine altered the effects of caffeine. HAL was infused via osmotic pumps (0.1 mg/kg/day) during a 14-day regimen of chronic caffeine administered in a caffeinated drinking solution ( approximately 136 mg/kg/day). HAL did not block the development of tolerance to the locomotor stimulant effects of caffeine, but did impair the recovery from tolerance following withdrawal of caffeine. [3H]SCH 23390 (DA D(1)) binding sites were downregulated in the nucleus accumbens and striatum and were upregulated in the prefrontal cortex of caffeine-treated vs. control rats; however, the affinity of [3H]SCH 23390 for these binding sites was unaltered. There were no differences between the caffeine-treated and control rats in number or affinity of [3H]spiperone (DA D(2)) binding sites. These results suggest that, although HAL did not alter the development of tolerance to caffeine, changes in DA D(1) receptors could be one component of the mechanism underlying caffeine-induced tolerance.


Subject(s)
Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Dopamine/physiology , Motor Activity/drug effects , Animals , Brain Chemistry/drug effects , Dopamine Antagonists/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Dose-Response Relationship, Drug , Drug Tolerance , Haloperidol/pharmacology , Male , Piperazines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/metabolism
7.
J Pharmacol Exp Ther ; 298(1): 156-64, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11408537

ABSTRACT

Pretreatment with morphine-like agonists potentiates the behavioral effects of opioid antagonists, possibly reflecting a state of acute physical dependence. Several studies have used operant behavior to quantify these effects. However, little research has been done using unconditioned behavior. One objective of this study was to determine whether opioid agonist pretreatment (e.g., morphine, fentanyl, and meperidine) potentiated naltrexone-induced suppression of water consumption following deprivation. Another objective was to determine whether the agonist pretreatment interval was functionally related to efficacy for the manifestation of acute dependence. Finally, we compared temporally the effects of the three agonists. Adult male Sprague-Dawley rats were water deprived for 18, 20, or 22 h and given an injection (s.c.) of an agonist or saline. After 1.75, 3.75, or 5.75 h, animals received a single dose (s.c.) of naltrexone (0.01-30 mg/kg) or saline. Fifteen minutes later, subjects had access to water for 30 min. A time course of antinociception was constructed after agonist administration, using the tail-flick procedure. All three agonists dose dependently potentiated naltrexone-induced drinking suppression, decreasing the ED50 of naltrexone by as much as 150-fold. There was no clear relationship between agonist efficacy and pretreatment interval. Sensitization to naltrexone was seen up to 6 h after agonist administration, occurring in the apparent absence of an antinociceptive effect. These data extend the range of behavioral effects of opioid antagonists potentiated by opioid agonist pretreatment to suppression of drinking and show that such potentiation can occur in the absence of a prototypical agonist effect.


Subject(s)
Analgesics, Opioid/pharmacology , Discrimination, Psychological/drug effects , Drinking/drug effects , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement/drug effects , Animals , Area Under Curve , Discrimination, Psychological/physiology , Dose-Response Relationship, Drug , Drinking/physiology , Fentanyl/pharmacology , Male , Meperidine/pharmacology , Morphine/pharmacology , Rats , Rats, Sprague-Dawley , Water Deprivation
8.
Drug Alcohol Depend ; 62(1): 83-90, 2001 Mar 01.
Article in English | MEDLINE | ID: mdl-11173171

ABSTRACT

Animals repeatedly administered drugs of abuse often become more sensitive to their effects. It has been proposed that this behavioral sensitization may serve as a useful model for changes that may underlie the etiology and maintenance of drug-seeking behavior. This study was designed to determine systematically some of the conditions of drug exposure under which sensitization occurs to morphine-induced stimulation of locomotor activity. Groups of rats (n=8 per group) were exposed to a regimen of intermittent morphine or saline injections for 1--4 days and tested at later time points with morphine or saline. The amount of behavioral sensitization observed was related to the number of drug exposures, but not to the dose of morphine used during drug exposures. Sensitization to morphine persisted for as long as 3 months and was completely blocked when naltrexone was administered with the test dose of morphine after the final morphine exposure. Administration of naltrexone with morphine during the exposure regimen did not alter the development of behavioral sensitization. These results indicate a robust behavioral sensitization to morphine that appears to be influenced in an orderly manner within a narrow window of the drug exposure conditions.


Subject(s)
Drug Tolerance , Morphine/administration & dosage , Motor Activity/drug effects , Narcotics/administration & dosage , Animals , Area Under Curve , Dose-Response Relationship, Drug , Male , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Rats , Rats, Sprague-Dawley
9.
Brain Res Bull ; 56(6): 545-51, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11786240

ABSTRACT

There have been studies of the discriminative effects of intracerebroventricularly (ICV)-administered morphine (MOR) in rats trained to discriminate MOR systemically, but the converse has not been done. In this study, rats were trained to discriminate between ICV (1-10 microg/3 microl, 1 h) or subcutaneous (SC) (3.0 mg/kg, 30 min) injections of MOR vs. saline/vehicle in a discrete-trial avoidance/escape procedure. On generalization testing, subjects in both the ICV- and SC-trained groups responded on the MOR-appropriate lever at ICV MOR doses < or =1-3 microg, and at SC MOR doses 2 to 3 orders of magnitude higher (vs. ICV). Naltrexone (SC) blocked the stimulus effects of MOR (ICV) equipotently in both training groups. In ICV-trained subjects, levorphanol (SC), the mu-opioid selective peptide [D-Ala2, NMePhe4, Gly-ol]-enkephalin (DAMGO) (ICV), and the enkephalinase inhibitor N-[L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-beta-alanine (SCH 32615) (ICV) produced complete MOR-appropriate responding, whereas the dextrorotary enantiomer of levorphanol dextrorphan (SC; < or = 3.0 mg/kg) and the delta-opioid selective peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE) (ICV, < or = 0.03 mg) did not. SC-trained subjects did not generalize to SCH 32615, which suggests qualitative differences in the discriminative stimulus effects of novel drugs as a function of the route of administration of the training drug. These data demonstrate that it is feasible to train rats to discriminate an opioid administered by the ICV route, and to perform extended tests of generalization to novel drugs (SC or ICV) in rats so trained.


Subject(s)
Brain/drug effects , Discrimination Learning/drug effects , Morphine/pharmacology , Narcotic Antagonists , Opioid Peptides/metabolism , Receptors, Opioid/agonists , Animals , Brain/metabolism , Discrimination Learning/physiology , Dose-Response Relationship, Drug , Drug Administration Routes , Drug Interactions/physiology , Enzyme Inhibitors/pharmacology , Injections, Intraventricular , Injections, Subcutaneous , Male , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Narcotics/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid/metabolism
10.
Pharmacol Biochem Behav ; 66(3): 517-22, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10899364

ABSTRACT

The results of a previous study in rats indicated that spiradoline has pharmacologically selective discriminative effects that are mediated by kappa-opioid receptors. However, the training dose, 3.0 mg/kg, increased response latencies, suggesting that it was relatively high. The current study was performed to characterize further the discriminative effects of spiradoline by using a lower training dose, 1.0 mg/kg, and testing a larger number of drugs for generalization with spiradoline. Rats were trained in a discrete-trial avoidance/escape procedure to discriminate 1.0 mg/kg spiradoline, SC, from saline in an average of 19.7 sessions; response latencies after saline and spiradoline were not different from each other. The rats generalized dose dependently and completely to other kappa-opioid agonists that have relatively high efficacy: ethylketocyclazocine, U69,593, and U50,488. They generalized partially to ketocyclazocine, (-)-N-allylnormetazocine, and DuP 747, and not at all to cyclazocine, butorphanol, nalorphine, and pentazocine, discriminable opioids that have relatively low efficacy at kappa-opioid receptors, or to morphine and dextromethorphan, discriminable drugs that do not act at kappa-opioid receptors. The discriminative effects of spiradoline were unaffected by the mu-opioid antagonist beta-funaltrexamine, but were blocked completely for at least 4 weeks by the kappa-opioid antagonist nor-binaltorphimine. Thus, spiradoline-like stimulus control of behavior remains kappa-opioid selective, and continues to have a high efficacy requirement even at a training dose that does not impair performance.


Subject(s)
Analgesics, Non-Narcotic/pharmacology , Benzeneacetamides , Discrimination Learning/drug effects , Naltrexone/analogs & derivatives , Pyrrolidines/pharmacology , Animals , Drug Interactions , Male , Morphine/antagonists & inhibitors , Morphine/pharmacology , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Nicotinic Antagonists/pharmacology , Pyrrolidines/antagonists & inhibitors , Rats , Rats, Sprague-Dawley , Receptors, Opioid, kappa/antagonists & inhibitors , Receptors, Opioid, kappa/metabolism , Tetrahydronaphthalenes/pharmacology
11.
Pharmacol Biochem Behav ; 65(1): 43-51, 2000 Jan 01.
Article in English | MEDLINE | ID: mdl-10638635

ABSTRACT

It has been reported that the discriminative stimulus effects of cocaine in squirrel monkeys can be potentiated by mu opioid agonists and attenuated by kappa opioid agonists. The purpose of this study was to extend these observations by examining the effects of mu and kappa opioids agonists on the discriminative stimulus effects of d-amphetamine (AMPH). Five squirrel monkeys were trained to discriminate 0.3 mg/kg of AMPH (i.m.) from saline using a stimulus termination/avoidance task. AMPH and cocaine substituted dose dependently for the AMPH training stimulus in all five monkeys. The AMPH training dose was completely antagonized by 0.1 mg/kg of the D1 dopamine antagonist SCH 39166. When administered alone, the kappa agonist U69,593 substituted partially or completely for AMPH in four of five monkeys, the kappa agonist enadoline substituted completely for AMPH in two of five monkeys, and morphine substituted completely for AMPH in one monkey. In all five monkeys, pretreatment with some doses of U69,593 or enadoline attenuated the discriminative stimulus effects of AMPH; however, some doses of U69,593 and enadoline also potentiated the effects of AMPH in at least two monkeys. Morphine pretreatment potentiated the discriminative stimulus effects of AMPH in three monkeys and either attenuated or did not alter these effects in two monkeys. Morphine pretreatment did not significantly alter the discriminative stimulus effects of cocaine except in one monkey. These data indicate large individual differences in the abilities of mu and kappa opioid agonists to alter the discriminative stimulus effects of AMPH.


Subject(s)
Benzeneacetamides , Benzofurans/pharmacology , Dextroamphetamine/pharmacology , Discrimination Learning/drug effects , Morphine/pharmacology , Pyrrolidines/pharmacology , Receptors, Opioid, kappa/agonists , Receptors, Opioid, mu/agonists , Animals , Cocaine/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Saimiri
12.
Psychopharmacology (Berl) ; 152(4): 431-9, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11140336

ABSTRACT

RATIONALE: According to recent studies daily, 3-h separations from the dam on postnatal days 2-14 produce long-lasting changes in responses to stressors and sensitivity to morphine in Long-Evans offspring. It has not been investigated whether daily dam-litter separations can have long-lasting effects also on the mother beyond weaning of the pups. OBJECTIVE: We tested whether dams that were separated from their litter for 3 h daily (LS) on postpartum days 2-14, like their offspring, exhibit altered anxiety-like behaviors and sensitivity to morphine, compared to dams that experienced only brief (15-min) separations (BS) from the litter or that were left undisturbed (NH) during the same period. METHODS: Four to six weeks after weaning, subjects were tested on the elevated plus-maze, in a novel locomotor activity arena, or were exposed to loud auditory stimuli. Sensitivity to morphine was assessed using hot-plate and tail-flick tests. RESULTS: LS dams spent significantly more time in the open arms of the plus-maze and in the center of the locomotor activity arena, and were more likely to emit ultrasonic vocalizations in response to auditory startle stimuli compared to NH dams. Furthermore, LS dams were less sensitive to morphine, primarily in the tail-flick test. Dams that experienced brief litter separations (BS), like LS dams, exhibited altered performance on the plus-maze and elevated ultrasonic vocalizations. However, BS dams were similar to NH controls in locomotor activity and sensitivity to morphine. CONCLUSIONS: Multiple postpartum separations from the offspring alter the behavior of Long-Evans dams in novel/aversive environments and affect their sensitivity to the antinociceptive effects of morphine.


Subject(s)
Analgesics, Opioid/pharmacology , Fear/drug effects , Morphine/pharmacology , Puerperal Disorders , Animals , Female , Male , Maze Learning/drug effects , Motor Activity/drug effects , Pain Measurement/drug effects , Puerperal Disorders/psychology , Rats , Rats, Long-Evans , Reflex, Startle/drug effects , Vocalization, Animal/drug effects
13.
Psychopharmacology (Berl) ; 153(1): 67-84, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11255930

ABSTRACT

BACKGROUND: The general premise that receptor theory provides a useful framework for understanding the behavioral effects of psychoactive drugs has been a central tenet of behavioral pharmacology. OBJECTIVES: The purpose of this review is to reiterate this basic theme and, in particular, the proposition that current concepts of pharmacological efficacy can be effectively used to examine behavioral effects of drugs with abuse or dependence potential in a way that contributes to the discovery of drugs to treat drug dependence. EXPERIMENTAL DATA: The review begins by briefly introducing the concept of efficacy and follows with several illustrations of how our current understanding of efficacy can be used to address important research questions in drug discovery. In the first, the likelihood of developing novel opioid analgesics with reduced abuse potential is addressed by considering the different efficacy requirements for the discriminative-stimulus and antinociceptive effects of mu-opioids. From a pharmacologically different perspective within drug abuse research, the review continues with an exposition of efficacy-related differences in the behavioral effects of dopamine D1 agonists and how such differences might be exploited in different medications strategies for treating cocaine dependence. The principles of pharmacological efficacy also have come to guide the development of novel GABAA-related antianxiety medications, and this is illustrated in a discussion of the utility of low-efficacy agonists in the treatment of benzodiazepine dependence. The second half of the paper provides counterpoint to the several examples of how principles of efficacy can be applied in drug discovery. The counterpoint includes, first, a critical evaluation of how the concept of efficacy has been applied in the development of monoamine transport inhibitors as anti-cocaine medications and, in particular, the difficulties this may pose for data analysis. The review ends with a discussion of efficacy-based analysis in drug discrimination research and illustrates some of the obstacles that may be encountered in pharmacologically classifying drugs on this basis. CONCLUSIONS: Ample evidence indicates that many receptor systems can be activated in a graded manner and that principles of efficacy can be judiciously applied to understand and exploit the behavioral effects of drugs that result from such graded activation. However, as cautioned in the last sections, the misapplication of pharmacological concepts in behavioral studies of drugs may obscure their behavioral pharmacology and potentially confound drug discovery.


Subject(s)
Dopamine Agonists/pharmacology , GABA Agonists/pharmacology , GABA-A Receptor Agonists , Receptors, Opioid/agonists , Substance-Related Disorders/drug therapy , Animals , Humans , Ligands
14.
Psychopharmacology (Berl) ; 148(3): 263-71, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10755739

ABSTRACT

RATIONALE: Four-hour pretreatment with a single dose of morphine or related opioids sensitizes rats responding for intracranial self-stimulation (ICSS) to the rate-decreasing effect of naltrexone, indicative of antagonist-precipitated withdrawal from acute opioid dependence. OBJECTIVES: To determine whether sensitization to naltrexone could be observed in morphine-pretreated rats responding under a progressive ratio (PR) schedule of ICSS and to determine whether acute pretreatment with benzodiazepines produces similar sensitization to flumazenil. METHODS: Rats with an electrode in the medial forebrain bundle were trained to respond under an ICSS PR schedule, in which the number of responses required for a 250-ms stimulus started at one, then increased gradually. If no responding occurred for 30 s, the response requirement reverted to a single response and the break point was operationally defined. RESULTS: Pretreatment (4-h) with 3.0 mg/kg or 5.6 mg/kg morphine reduced the ED25 values of naltrexone for decreasing response rate from 18+/-6.7 mg/kg to 0.021+/-0.006 mg/kg and 0.006+/-0.001 mg/kg, respectively. Changes in break point usually paralleled changes in response rate. In contrast, 4- to 24-h pretreatment with the benzodiazepines chlordiazepoxide (30 mg/kg and 100 mg/kg) or diazepam (3.0 mg/kg and 10 mg/kg), behaviorally-active doses, did not significantly alter sensitivity to the effects of flumazenil (1.0-30 mg/kg). CONCLUSIONS: These results show that PR ICSS provides a stable behavioral baseline for testing drugs in rats and extend to this procedure the generality of the phenomenon of acute opioid dependence. There was no comparable evidence of acute benzodiazepine dependence, suggesting that there are differences in the ways that opioid and benzodiazepine agonists initiate the adaptive changes that underlie the state of physical dependence.


Subject(s)
Benzodiazepines/pharmacology , Brain/physiology , Opioid-Related Disorders/physiopathology , Substance-Related Disorders/physiopathology , Animals , Diazepam/pharmacology , Dose-Response Relationship, Drug , Flumazenil/pharmacology , Male , Morphine/pharmacology , Naltrexone/pharmacology , Rats , Rats, Sprague-Dawley , Reinforcement Schedule , Self Stimulation
15.
Pharmacol Biochem Behav ; 64(3): 487-93, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10548260

ABSTRACT

Morphine indirectly enhances dopaminergic activity in the nigrostriatal system, and repeated administration of morphine progressively increases the locomotor activity of rats. We used the rotational behavior model to determine if daily morphine produces an increase in turning and produces cross-sensitization to d-amphetamine and cocaine. Rats with unilateral nigrostriatal lesions received daily injections of saline or morphine (10 mg/kg). Repeated morphine administration produced a progressive increase in turning over 13 days. Next, a morphine dose-response curve (1.0-30 mg/kg) was determined. Both the saline and morphine-treated groups showed dose-dependent increases in turning, but, the peak effect in the morphine group was higher than that in the saline group, indicating sensitization to morphine. The morphine-treated group did not show cross-sensitization to either d-amphetamine (0.1-3 mg/kg) or cocaine (1.0-30 mg/kg); in fact, it showed less cocaine-induced turning than the saline group. Seventy-one days after saline or morphine injections began, the morphine group was still significantly more sensitive to turning induced by 10 mg/kg morphine than the saline group was (200 vs. 750). Therefore, repeated daily injections of morphine produce a progressive sensitization to turning induced by morphine in the absence of cross-sensitization to turning induced by psychomotor stimulants.


Subject(s)
Analgesics, Opioid/pharmacology , Morphine/pharmacology , Substantia Nigra/physiology , Amphetamine/pharmacology , Animals , Central Nervous System Stimulants/pharmacology , Cocaine/pharmacology , Dopamine/physiology , Dopamine Uptake Inhibitors/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Male , Rats , Rats, Sprague-Dawley , Stereotyped Behavior/drug effects
16.
Eur J Pharmacol ; 376(1-2): 7-15, 1999 Jul 02.
Article in English | MEDLINE | ID: mdl-10440083

ABSTRACT

9-Chloro-2-(2-furyl)[1,2,4]triazolol[1,5-c]quinazolin-5-amin e (CGS 15943), like caffeine, is an antagonist at adenosine A1 and A2A receptors and a behavioral stimulant in animals. The two drugs have overlapping discriminative effects. Enhancement of dopamine-mediated neurotransmission appears to contribute to the behavioral effects of caffeine. This study was conducted to determine if there is a dopamine component to the discriminative effects of CGS 15943. Squirrel monkeys discriminating between i.m. injections of 1.0 mg/kg CGS 15943 and vehicle generalized dose-dependently and completely to eight dopamine receptor agonists that encompass a variety of mechanisms and sites of action, both pre- and postsynaptic. The discriminative effects of the training dose of CGS 15943 were blocked dose-dependently and completely by the dopamine receptor antagonists R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaz epine (SCH 23390; D1) and eticlopride (D2). Thus, the discriminative effects of CGS 15943 have a dopamine component that appears to be mediated by both the D1 and D2 families of dopamine receptors. The monkeys also generalized to selective inhibitors of the neuronal transporters of norepinephrine (nisoxetine) and serotonin (fluoxetine), indicating that monoamines other than dopamine also contribute to the discriminative effects of CGS 15943.


Subject(s)
Dopamine/physiology , Purinergic P1 Receptor Antagonists , Quinazolines/pharmacology , Triazoles/pharmacology , Animals , Cocaine/pharmacology , Dextroamphetamine/pharmacology , Discrimination Learning/drug effects , Discrimination Learning/physiology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Generalization, Stimulus/drug effects , Male , Morphine/pharmacology , Neurons/drug effects , Neurons/metabolism , Norepinephrine/antagonists & inhibitors , Norepinephrine/metabolism , Phencyclidine/pharmacology , Receptor, Adenosine A2A , Receptors, Biogenic Amine/antagonists & inhibitors , Saimiri , Selective Serotonin Reuptake Inhibitors/pharmacology
17.
Eur J Pharmacol ; 377(1): 21-8, 1999 Jul 14.
Article in English | MEDLINE | ID: mdl-10448921

ABSTRACT

Eight kappa-opioid receptor agonists were examined for their effects in squirrel monkeys responding under a fixed interval 3-min schedule of stimulus termination. Six of these kappa-opioid receptor agonists decreased dose-dependently the total number of responses and with an order of potency consistent with kappa-opioid receptor interaction. Three of these kappa-opioid receptor agonists, bremazocine, U69,593 [[(5a,7a,8b)-(+)-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)] benzeneacetamide] and enadoline, were evaluated following pretreatment with 1.0 mg/kg of naltrexone or 3.0 mg/kg of norbinaltorphimine. The effects of the three agonists were antagonized significantly by naltrexone, but only those of bremazocine and U69,593 were antagonized significantly by norbinaltorphimine. Statistical analysis of the data averaged over six monkeys revealed that naltrexone was significantly more potent than norbinaltorphimine at antagonizing enadoline and U69,593, but naltrexone and norbinaltorphimine were equipotent at antagonizing bremazocine. Moreover, naltrexone was 8-fold more potent at antagonizing U69,593 and enadoline than at antagonizing bremazocine. These results suggest that under these conditions the effects of U69,593 and enadoline may be mediated, in part, by a different receptor population, perhaps a subtype of kappa-opioid receptors, from the one that mediates the effects of bremazocine.


Subject(s)
Behavior, Animal/drug effects , Benzeneacetamides , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Receptors, Opioid, kappa/agonists , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , Analgesics/pharmacology , Animals , Benzofurans/pharmacology , Benzomorphans/pharmacology , Conditioning, Operant , Dose-Response Relationship, Drug , Ethylketocyclazocine/pharmacology , Nalorphine/pharmacology , Pyrroles/pharmacology , Pyrrolidines/pharmacology , Reinforcement Schedule , Saimiri , Thiophenes/pharmacology
18.
J Med Chem ; 42(5): 882-95, 1999 Mar 11.
Article in English | MEDLINE | ID: mdl-10072685

ABSTRACT

As part of a program to develop site-specific medications for cocaine abuse, a series of 2-(aminomethyl)-3-phenylbicyclo[2.2.2]- and -[2.2.1]alkane derivatives was synthesized and tested for inhibitory potency in [3H]WIN 35,428 binding and [3H]dopamine uptake assays using rat striatal tissue. Selected compounds were tested for their ability to substitute for cocaine in rat drug discrimination tests. Synthesis was accomplished by a series of Diels-Alder reactions, using cis- and trans-cinnamic acid derivatives (nitrile, acid, acid chloride) with cyclohexadiene and cyclopentadiene. Standard manipulations produced the aminomethyl side chain. Many of the compounds bound with high affinity (median IC50 = 223 nM) to the cocaine binding site as marked by [3H]WIN 35,428. Potency in the binding assay was strongly enhanced by chlorine atoms in the 3- and/or 4-position on the aromatic ring and was little affected by corresponding methoxy groups. In the [2.2.2] series there was little difference in potency between cis and trans compounds or between N, N-dimethylamines and primary amines. In the [2.2.1] series the trans exo compounds tended to be least potent against binding, whereas the cis exo compounds were the most potent (4-Cl cis exo: IC50 = 7.7 nM, 27-fold more potent than 4-Cl trans-exo). Although the potencies of the bicyclic derivatives in the binding and uptake assays were highly correlated, some of the compounds were 5-7-fold less potent at inhibiting [3H]dopamine uptake than [3H]WIN 35,428 binding (for comparison, cocaine has a lower discrimination ratio (DR) of 2.5). The DR values were higher for almost all primary amines and for the trans-[2.2.2] series as compared to the cis-[2.2.2]. Most of the compounds had Hill coefficients approaching unity, except for the [2. 2.2] 3,4-dichloro derivatives, which all had nH values of about 2.0. Two of the compounds were shown to fully substitute for cocaine in drug discrimination tests in rats, and one had a very long duration of action.


Subject(s)
Bridged Bicyclo Compounds/chemical synthesis , Cocaine-Related Disorders/drug therapy , Dopamine Uptake Inhibitors/chemical synthesis , Animals , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/metabolism , Bridged Bicyclo Compounds/pharmacology , Cocaine/analogs & derivatives , Cocaine/metabolism , Discrimination Learning/drug effects , Dopamine/metabolism , Dopamine Uptake Inhibitors/chemistry , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacology , In Vitro Techniques , Male , Models, Molecular , Neostriatum/metabolism , Neostriatum/ultrastructure , Protein Binding , Rats , Rats, Sprague-Dawley , Stereoisomerism , Structure-Activity Relationship , Synaptosomes/metabolism
19.
Pharmacol Biochem Behav ; 62(2): 247-53, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9972691

ABSTRACT

Cocaine can produce antinociception in a number of animal models. The present experiments were designed to determine if opioid receptor agonists modulate cocaine-induced antinociception in rats. Cocaine produced a dose-dependent increase in antinociception in the hot-plate, but not paw-pressure, test. The combination of cocaine and morphine or [D-Pen2, D-Pen5]enkephalin (DPDPE) produced results no greater than simple additivity in the hot-plate test. However, the combination of cocaine and morphine produced greater antinociception than morphine alone in the paw-pressure test. A low dose of U69,593 potentiated the effects of cocaine in the hot-plate test. In contrast, cocaine attenuated the effect of U69,593 in the paw-pressure test. Both naltrexone and the selective kappa-opioid receptor antagonist nor-binaltorphamine (nor-BNI) blocked the potentiation of cocaine-induced antinociception by U69,593. The combination of U69,593 and cocaine can produce superadditive or subadditive effects, depending upon the doses and antinociceptive assay used.


Subject(s)
Benzeneacetamides , Cocaine/pharmacology , Pain , Receptors, Opioid/agonists , Analgesics/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Synergism , Enkephalin, D-Penicillamine (2,5)- , Enkephalins/pharmacology , Male , Morphine/pharmacology , Pain Measurement , Pyrrolidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, kappa/agonists
20.
J Pharmacol Exp Ther ; 288(3): 1269-77, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10027868

ABSTRACT

The discriminative stimulus effects of an acute morphine (MOR) --> naltrexone (NTX) combination were characterized and compared with the stimulus effects of NTX-precipitated and spontaneous withdrawal from chronic MOR administration. Adult male Sprague-Dawley rats (n = 6-8) were trained to discriminate between two drug treatments in a discrete-trial avoidance/escape procedure: MOR (10 mg./kg, s.c., 4 h) --> NTX (0.3 mg/kg, s.c., 0.25 h) versus saline (SAL, 1 ml/kg, s. c., 4 h) --> NTX (0.3 mg/kg, s.c., 0.25 h). Subjects responded only on the SAL --> NTX-appropriate lever when SAL was given 3.75 h after MOR or 3.75 h before any dose of NTX (0.3-100 mg/kg). Responding was dose dependent and MOR --> NTX-appropriate when NTX (0.01-0.1 mg/kg) followed MOR. Full MOR --> NTX-appropriate responding was dependent on the pretreatment dose and time of MOR, with full effects observed only when MOR (10 mg/kg) was given 3 to 4 h before NTX. While subjects were maintained on either 20- or 40 mg/kg/day of MOR via osmotic pump, NTX produced full dose-dependent, MOR --> NTX-appropriate responding. When the MOR-filled pumps were removed, partial MOR --> NTX-appropriate responding occurred, peaking at 6 to 12 h. The physical withdrawal signs produced by NTX after acute or during chronic MOR exposure were of smaller magnitude compared with the ones that occurred during abrupt withdrawal from chronic MOR. A qualitatively unique "withdrawal" stimulus that is dose- and time-dependent appears to be the basis of this MOR --> NTX discrimination.


Subject(s)
Discrimination Learning/drug effects , Morphine/administration & dosage , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Narcotics/administration & dosage , Animals , Dose-Response Relationship, Drug , Drug Interactions , Male , Rats , Rats, Sprague-Dawley , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...